Launch of more than 10 socially significant drugs of our own full-cycle production, used in various therapeutic areas: oncology, autoimmune, neurological, metabolic, infectious diseases.

Phase II of clinical trials of the oral drug AB5080 with a broad spectrum of anti-influenza activity has been successfully completed. As a result of the studies, the drug demonstrated the best safety profile and good tolerability by patients with no adverse events typical for drugs of this class.

Also this year, phase II of clinical trials of the innovative drug AVN-101 for the treatment of generalized anxiety disorder was successfully completed. The study proved the safety of the drug and the possibility of its use as a long-term therapy.